Viewbix (VBIX) 10-K 29 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 28, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Virtual Crypto Technologies, Inc.
Entity Central Index Key	0000797542
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 2,027,245
Entity Common Stock, Shares Outstanding		110,749,643
Trading Symbol	VRCP
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 499,919	$ 2,959
Marketable securities	17,242
Other current assets	41,516	12,222
Total current assets	558,677	15,181
Restricted cash		59
Property and Equipment, net		14,290
Total assets	558,677	29,530
Current liabilities:
Accounts payable and accrued liabilities	13,115	123,719
Accounts payable - related party
Employee payable	7,064
Short term portion of convertible notes (Note 3)	485,449	352,447
Liabilities held for sale (Note 1C)	469,525	535,775
Total current liabilities	975,153	1,011,941
Convertible notes (Note 3)		606,165
Total liabilities	975,153	1,618,106
Stockholders' deficit (Note 4)
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none and 529 issued at December 31, 2018 and December 31, 2017, respectively.			[1]
Common stock, $0.0001 par value; 490,000,000 shares authorized; 110,748,391 and 22,543,008 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively.	11,075	2,255
Accumulated other comprehensive income	(19,337)	(19,337)
Additional paid-in capital	41,218,691	14,968,925
Receipt on account of shares		80,000
Accumulated deficit	(41,626,905)	(16,620,419)
Total stockholders' deficit	(416,476)	(1,588,576)
Total liabilities and stockholders' deficit	$ 558,677	$ 29,530
[1]	less than $1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	529
Preferred stock, shares outstanding	529
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares issued	22,543,008	110,748,391
Common stock, shares outstanding	22,543,008	110,748,391
Stock conversion, description	less than $1

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues (Note 1D)	$ 100,000
Expenses:
Research and development	(790,413)
General and administrative (Note 6)	(1,773,839)	(557,300)
Total operating expenses	(2,564,252)	(557,300)
Operation Loss	(2,464,252)	(557,300)
Finance expense:
Finance expense, net (Note 7)	(22,542,234)	(307,516)
Net loss from continuing operations available to shareholders of the company	(25,006,486)	(864,816)
Net loss from discontinued operations available to shareholders of the company) Note 1C)		(709,090)
Net loss from continuing operations attributable to shareholders of the company	(25,006,486)	(1,573,906)
Net loss attributable to shareholders of preferred stock		39,491
Net loss from continuing operations	$ (25,006,486)	$ (1,534,415)
Basic and diluted net loss per share
From continuing operations	$ (0.41)	$ (0.04)
From discontinued operations		$ (0.03)
Weighted average shares outstanding - basic and diluted	61,165,674	21,780,899

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Preferred Stock [Member]		Additional Paid-in Capital [Member]	Receipt on Account of Shares [Member]	Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 1,994			$ 13,826,957		$ (19,337)	$ (15,046,513)	$ (1,236,899)
Balance, shares at Dec. 31, 2016	19,931,478
Common stock issued for cash	$ 132			526,081				526,213
Common stock issued for cash, shares	1,315,563
Cashless exercise of Warrants	$ 110			(110)
Cashless exercise of Warrants, shares	1,096,395
Conversion of Convertible Note to shares	$ 7			10,393				10,400
Conversion of Convertible Note to shares, shares	74,572
Issuance of Ordinary Shares	$ 12			(12)
Issuance of Ordinary Shares, shares	125,000
Issuance of Preferred Stock			[1]	529,000				529,000
Issuance of Preferred Stock, shares		529
Receipt on Account of Shares					80,000			80,000
Receipt on Account of Shares, shares
Share based compensation				76,616				$ 76,616
Exercise of stock options, shares
Net loss for the year							(1,573,906)	$ (1,573,906)
Balance at Dec. 31, 2017	$ 2,255			14,968,925	80,000	(19,337)	(16,620,419)	(1,588,576)
Balance, shares at Dec. 31, 2017	22,543,008	529
Cashless exercise of Warrants
Share based compensation								1,150,675
Common stock and warrants issued for cash	$ 2,770			1,938,180				1,940,950
Common stock and warrants issued for cash, shares	27,697,855
Common stock issued for services	$ 433			1,003,866				1,004,299
Common stock issued for services, shares	4,329,999
Warrants issued for services				146,376				146,376
Exercise of stock options	$ 6			57				$ 63
Exercise of stock options, shares	62,500							62,500
Issuance of new convertible note with a beneficial conversion feature				100,000				$ 100,000
Change is the terms of Convertible Note				22,581,508				22,581,508
Partial conversion of convertible note to shares	$ 5,554			549,836				555,390
Partial conversion of convertible note to shares, shares	55,543,600
Cancellation of Preferred Shares				(150,000)				(150,000)
Cancellation of Preferred Shares, shares		(529)
Issuance of Shares in respect of proceeds received during 2017	$ 57			79,943	(80,000)
Issuance of Shares in respect of proceeds received during 2017, shares	571,429
Net loss for the year							(25,006,486)	(25,006,486)
Balance at Dec. 31, 2018	$ 11,075			$ 41,218,691		$ (19,337)	$ (41,626,905)	$ (416,476)
Balance, shares at Dec. 31, 2018	110,748,391
[1]	less than $1

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)	12 Months Ended
	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Stock conversion, description	less than $1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Activities:
Net loss	$ (25,006,486)	$ (1,573,906)
Depreciation	14,290	17,513
Amortization of debt discount	1,040,838	350,208
Loss from marketable securities	32,758
Shares and Warrants issued for services	1,150,675
Share based compensation		76,616
Finance loss arising from change in terms of convertible notes	21,472,897
Change in derivative liability		(336,272)
Non cash finance, general and administrative expenses arising from settlement with debt and warrant holders		659,960
Decrease in liabilities held for sale	(66,250)
Decrease in deferred revenues	(50,000)
Increase (decrease) in accounts payable and accrued liabilities	(103,051)	189,461
Decrease in amounts due from related party		(40,339)
Decrease in accrued interest		35,078
Increase in other receivables	(29,724)	(2,866)
Net cash used in operating activities	(1,544,053)	(630,015)
Investing Activities:
Decrease in restricted cash		11,866
Net cash provided by investing activities		11,866
Financing Activities:
Issuance of common stock (net of issuance expenses)	1,940,950	526,342
Issuance of short-term convertible notes	100,000
Receipt on account of stock		80,000
Exercise of options	63
Net cash provided by financing activities	2,041,013	606,342
Net increase (decrease) in cash	496,960	(2,527)
Cash and cash equivalents - beginning of period	2,959	4,486
Cash and cash equivalents - end of period	499,919	2,959
Non-cash transactions:
Deferred revenues against Marketable securities	50,000
Common stock issued in respect of proceeds received during 2017	80,000
pursuant to convertible note	555,390
Issuance of Preference Shares in connection with settlement with debt and warrant holders		529,000
Settlement agreement with debt and warrant holders accounted for as extinguishment and re issuance of debt:
Extinguishment of convertible note		659,960
Re issuance of convertible note		$ 470,200

General

General	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
General	Note 1. General A. Virtual Crypto Technologies, Inc., f/k/a Emerald Medical Applications Corp. (the “Company(, was incorporated in the State of Ohio in 1989 under a predecessor name, Zaxis International, Inc. (“Zaxis”). On August 25, 1995, Zaxis merged with a subsidiary of The InFerGene Company, a Delaware corporation, which entity changed its name to Zaxis International, Inc. and the Company was reincorporated in Delaware under the name of Zaxis International, Inc. On December 30, 2014, Zaxis entered into an agreement with Emerald Medical Applications Ltd., a private limited liability company organized under the laws of the State of Israel (“Emerald Israel”). On March 16, 2015, Zaxis and Emerald Israel executed the Share Exchange Agreement, which closed on July 14, 2015 (the “Share Exchange Agreement”) and Emerald Israel became the Company’s wholly-owned subsidiary. Emerald Israel was engaged in the business of developing Emerald Israel’s DermaCompare technology and the development, sale and service of imaging solutions utilizing its DermaCompare software for use in derma imaging and analytics for the detection of skin cancer. During the fourth quarter of 2015, in connection with the Share Exchange Agreement, the Company changed its name to Emerald Medical Applications Corp. B. On January 4, 2018, the Company and Emerald Israel entered into an agreement with Alpha Capital Ansalt and Chi Squared Inc. (collectively, the “Preferred Shareholders”), pursuant to which the Preferred Shareholders agreed to cancel their shares of Series A Preferred Convertible Stock in return for the receipt of up to $250,000 of proceeds from the liquidation of Emerald Israel, to the extent that such liquidation yields net positive proceeds (“Excess Net Assets”). Management’s best estimate of the potential value of the Excess Net Assets at the date of the cancellation of the shares of Series A Preferred Convertible Stock was $150,000 and therefore, the Company recorded a charge to Additional Paid-in Capital in the Statement of Changes in Stockholders’ Deficit with a corresponding credit to liabilities. Management’s best estimate of the potential value of the Excess Net Assets as of December 31, 2018, was nil. Accordingly, the Company recorded a finance income of $150,000 in its Consolidated Statements of Comprehensive Loss a result of the reversal of the relating liability. As such, as of December 31, 2018, there were no shares of Series A Preferred Convertible Stock outstanding. C. On January 29, 2018, the Company ceased the DermaCompare operations of Emerald Israel and on May 2, 2018, the District Court of Lod, Israel issued a winding-up order for Emerald Israel and nominated an Israeli advocate (attorney) as a special executor for Emerald Israel. Following the cessation of the DermaCompare operations, the Company classified to discontinued operations its 2017 results of operation and balances relating to the DermaCompare operation. Liabilities held for sale: December 31, 2018 December 31, 2017 Accounts payable and accrued liabilities 287,070 321,934 Accounts payable - related party 76,004 82,331 Employee payable 75,955 98,476 Short term portion of convertible notes 30,496 33,034 Total 469,525 535,775 D. On January 17, 2018, the Company formed a new wholly-owned subsidiary in Israel, Virtual Crypto Technologies Ltd. (the “New Subsidiary” or “Virtual Crypto Israel”), to develop and market software and hardware products facilitating, allowing and supporting purchase and/or sale of cryptocurrencies through ATMs, tablets, personal computers and/or mobile devices. On January 24, 2018, Virtual Crypto Israel had entered into a binding term sheet (the “Chiron Term Sheet”) with Chiron Refineries Ltd. (“Chiron”), a public company listed on the Tel-Aviv Stock Exchange (TASE: CHR). Pursuant to the Chiron Term Sheet: (i) Virtual Crypto Israel agreed to appoint a wholly-owned subsidiary of Chiron, to be organized under the laws of the Turkish Republic of Northern Cyprus (the “Distributor”), as the exclusive distributor of Virtual Crypto Israel’s Products in Turkey, including the territory of Turkish Republic of Northern Cyprus (collectively, the “Territory”); and (ii) the Distributor shall have the right to appoint sub-distributors within the Territory. The appointment of the Distributor was subject to the payment by the distributor to Virtual Crypto Israel of $250,000 as an appointment fee, of which $150,000 was to be deemed an advance payment by the distributor made on account of future purchases of the Company’s Products. Virtual Crypto Israel further granted the Distributor an option, exercisable by the Distributor within 12 months from the date on which the ATM Product, including the related software and hardware, was fully tested and ready for installation and operation, to be appointed as an exclusive distributor of the Products for the Federal Republic of Nigeria. If the option was exercised, the Distributor was required to pay Virtual Crypto Israel an appointment fee not more than $250,000. In November 2018, Chiron reported that it had encountered financial difficulties and as such the Company will no longer pursue the transactions contemplated by the Chiron Term Sheet. To date, $100,000 was paid by the Distributor to Virtual Crypto Israel, which has been recognized as revenues for the year ended December 31, 2018. E. Going Concern: The Company has incurred significant operating losses and negative cash flows from operating activities in relation to its operations, since inception. While the Company raised approximately $1.9 million in the year ended December 31, 2018 to fund the operations of its New Subsidiary, the Company will require additional capital resources in order to support the commercialization of the New Subsidiary’s technology and operations and maintain its research and development activities related to the New Subsidiary’s technology. The Company is addressing its liquidity needs by seeking additional funding from public and/or private sources. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the Company’s short and long-term requirements, or at all these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP). Use of estimates in the preparation of consolidated financial statements This Management’s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. As applicable to the consolidated financial statements included elsewhere in this report, the most significant estimates and assumptions relate to (i) the going concern assumptions, (ii) measurement of Convertible Note. Functional currency The functional currency of the Company and its subsidiary is the US dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, “Foreign Currency Matters” (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Cash and cash equivalents The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents. Marketable Securities The Company accounts for investments in marketable securities in accordance with ASC Topic 320-10, “Investments - Debt and Equity Securities” Property and equipment 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations. 2. Rates of depreciation: % Computers 33 Furniture and office equipment 7-15 Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment losses. Accounting For Obligations And Instruments Potentially To Be Settled In The Company’s Own Stock: We account for obligations and instruments potentially to be settled in the Company’s stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This guidance addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company’s own stock. Fair Value of Financial Instruments: FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2018 and 2017, the carrying value of certain financial instruments (cash and cash equivalents, other current assets, accounts payable and accrued expenses and employee payable.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. The Company measures its derivative warrant liabilities at fair value at each period. The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Accounting For Convertible Debt Instruments We account for convertible debt instruments, which do not meet the definition of a derivative financial instrument per FASB ASC 815, Accounting for Derivative Financial Instruments, in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. This guidance addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Discount on the debt component resulting from allocation of proceeds to the equity component is amortized in the profit and loss statement as finance expense. Allocation of proceeds into equity and debt components of convertible notes issued together with other detachable financial instruments is performed, in relation to the proceeds allocated to the convertible notes, based on the relative fair value of such convertible notes and the other detachable financial instruments issued. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors (including employee stock options under the Company’s stock plans) based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award, net of estimated forfeitures. The Company estimates the fair value of stock options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company. Earnings per Common Share Basic net loss per share is computed by dividing net loss, as adjusted to include the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis. Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2018 and December 31, 2017, since all such securities have an anti-dilutive effect. Revenue recognition The Company follows paragraph 605-10-S99 of the FASB Accounting Standards Codification Research and development expenses, net: Research and development expenses are charged to the statement of operations as incurred. Income Taxes: We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for consolidated financial statements purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and consolidated financial statements purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Uncertain Tax Positions : When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Contingencies The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred. Recently issued accounting pronouncements 1. Accounting Standard Update 2014-09, “Revenue from Contracts with Customers” Commencing January 1, 2018, the Company adopted Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in ASU 2014-09 using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. During 2016, the FASB issued several Accounting Standard Updates (“ASUs”) that focus on certain implementation issues of the new revenue recognition guidance including Narrow-Scope Improvements, Practical Expedients and technical corrections. In accordance with an amendment to ASU 2014-09, introduced by Accounting Standard 2015-14, “Revenue from contracts with Customers – Deferral of the Effective Date”, for a public entity, the amendments in ASU 2014-09 became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). The adoption of ASU 2014-09 did not have a significant impact on its consolidated financial statements. 2. Accounting Standard Update (ASU) No. 2017-11, “ Earnings Per Share” In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Among others, Part I of ASU 2017-11 simplifies the accounting for certain financial instruments with down round features, which is a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Current accounting guidance creates cost and complexity for organizations that issue financial instruments with down round features by requiring, on an ongoing basis, fair value measurement of the entire instrument or conversion option. ASU 2017-11 require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. ASU 2017-11 also addresses navigational concerns within the FASB Accounting Standards Codification related to an indefinite deferral available to private companies. The provisions of the new ASU related to down rounds are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 (fiscal 2019 for the Company). Early adoption is permitted for all entities. The adoption of ASU 2017-11 did not have a significant impact on its consolidated financial statements 3. Accounting Standard Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In June 2018, the FASB issued Accounting Standard Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (ASU 2018-07). ASU 2018-07 aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 will be measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the goods has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based payment awards will be measured at the grant date. With respect to awards with performance conditions, ASU 2018-07 concludes that, consistent with the accounting for employee share-based payment awards, an entity will consider the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions. ASU 2018-07 also requires that the classification of equity classified nonemployee share-based payment awards will continue to be subject to the requirements of Topic 718 unless the award was modified after the goods has been delivered, the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing goods or services. This eliminates the requirement to reassess classification of such awards upon vesting. In addition, ASU 2018-07 includes certain Non-public Entity-Specific Amendments. ASU 2018-07 is effective for Public entities in annual periods beginning after 15 December 2018, and interim periods within those years (first quarter of 2019 for the Company). Early adoption is permitted, including in an interim period, but not before an entity adopts the new revenue guidance (which was adopted by the Company in its interim financial statements for 2018). An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity-classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these nonemployee awards at fair value as of the adoption date. The Company is evaluating the impact of ASU 2018-07 on its financial statements. 4. In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2016-02 (Topic 842) “Leases”. Topic 842 supersedes the lease requirements in Accounting Standards Codification (ASC) Topic 840, “Leases”. Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. ASU No. 2016-02 is effective for interim and annual reporting periods beginning after December 15, 2018. In July 2018, the FASB issued amendments in ASU 2018-11, which provide a transition election to not restate comparative periods for the effects of applying the new standard. This transition election permits entities to change the date of initial application to the beginning of the earliest comparative period presented, or retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures. 5. Commencing January 1, 2018, the Company adopted ASU 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash” (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. This guidance did not have a material impact on the Company’s consolidated financial statements.

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Convertible Notes	Note 3 - Convertible Notes A. On August 7, 2017, the Company entered into the settlement agreement with Alpha and Chi Squared Capital Inc. as a result of the fact that Alpha and Chi Squared had taken the position that certain defaults may have occurred as a result of actions and/or inactions by the Company with respect to the Company’s obligations under convertible notes (the “Notes”) issued during 2016, which the Company did not deem to be defaults (the “Settlement Agreement”). Pursuant to the Settlement Agreement, the Notes, which had originally provided for a maturity date of June 19, 2017 and were in the original principal amounts of $400,000 and $40,000, respectively, were extended until June 19, 2019, in consideration for which the Company agreed to an increase in the principal amounts to $551,600 and $55,160, respectively, both of which retain the adjusted conversion price of $0.14, calculated in accordance with the terms of the original Notes. Such conversion price is subject adjustments in the event of future financing at a price of less than $0.14 per share. As a further part of the settlement, the Company agreed to issue Alpha and Chi Squared a total of 528.82 newly authorized shares of Series A Convertible Preferred Stock having a stated value and liquidation preference of $1,000 per share, and are convertible into a total of 3,778,647 shares based upon a conversion price of $0.14 per share, subject to adjustment in the event of a future financing such that the amount of ordinary shares to be issued pursuant to conversion of Series A Convertible Preferred Stock will represent the value of $1,000, per 1 Series A Convertible Preferred Stock, based on a conversion price which is identical to the ordinary share price at which securities are offered in such future financing. The Series A Convertible Preferred Stock shall be entitled to receive dividends on the same basis as Ordinary Shares and shall have no voting rights. As part of the Settlement Agreement, the Company extended the Alpha Chi Option to July 15, 2018. The settlement was accounted for as extinguishment of the pre-settlement notes and re issuance of the Notes and Series A Convertible Preferred Stock. As a result of the Settlement Agreement, the Company recorded a charge to general and administrative expenses in the Statement of Operation Losses of $440,684 representing the penalties and liquidation damages portion of the above-mentioned provision, and $219,276 was charged to finance expenses in the Statement of Operating Losses. The Series A Convertible Preferred Stock were recorded in shareholders’ equity at their fair value at the effective date of the settlement. As the Company concluded the conversion feature embedded in the amended notes is not a beneficial conversion feature pursuant to the provisions of ASC 470-20 (“Debt with Conversion and Other Options”), the post amendment carrying amount of the convertible notes, which was based on the fair value of the convertible notes at the effective date of the settlement, was recorded in liabilities in its entirely. The Company accounts for options to purchase convertible notes and warrants (refer to the Alpha Chi Option above) as derivative liabilities that are measured at their far value at each period end, in accordance with ASC 815 (“Derivatives and Hedging”). The Company uses directly observable inputs as well as significant unobservable inputs in the valuation of these derivative liabilities. The inputs used in the valuation are risk free interest rate, expected volatility, expect option term, expected dividend yield and Company specific discount rate. On January 24, 2018, Alpha Anstalt Capital (“Alpha”), Chi Squared Capital (“Chi”), Firstfire Global Opportunities Fund LTC, Goldmed Ltd, IlanMalca and Maz Partners, former holders of the Company’s convertible notes, sold their convertible notes previously issued by the Company in the aggregate amount of $958,611 (the “January 2018 Convertible Notes”) to certain new third-party accredited investors (the “New Investors”) and, in connection therewith, the Company and the New Investors agreed to: (i) amend the conversion price of the January 2018 Convertible Notes from $0.014 to $0.01; (ii) cancel the Class A warrants and Class B warrants issued together with the January 2018 Convertible Notes (see Note 4 Stockholders’ Equity for accounting treatment of the cancelled warrants); (iii) amend the interest rate from 8% to 1% per annum under the January 2018 Convertible Notes; (iv) extend the repayment/maturity date on the January 2018 Convertible Notes to January 23, 2019 (see Subsequent Events Note 10 ); and (iv) cancel the options granted to Alpha and Chi in July 2016 (the “Alpha-Chi Options”). The change in terms of the January 2018 Convertible Notes, including the cancellation of the above-referenced warrants, was accounted for as an extinguishment of the convertible notes and the issuance of new convertible notes. The Company recorded a finance expense in the amount of $21,622,897 in the Statement of Comprehensive Loss and an increase to Additional Paid-in Capital in the Statement of Stockholders’ Deficit of $22.6 million as a result of the transaction. The Company further concluded that the post-amended January 2018 Convertible Notes contain a -beneficial conversion feature equal to the par value of the January 2018 Convertible Notes ($958,611) and accordingly, recorded a discount on the January 2018 Convertible Notes, to be amortized to finance expense in the Statement of Comprehensive Loss over the term of the January 2018 Convertible Notes. On January 24, 2018, $73,000 of the January 2018 Convertible Notes was converted, at the adjusted conversion price of $0.01 per share, into 7,300,000 shares of the Company’s common stock and on March 19, 2018, a further $9,218 of the January 2018 Convertible Notes were converted, at the adjusted conversion price of $0.01 per share, into 921,800 shares of the Company’s common stock and on December 9, 2018, $465,172 of the January 2018 Convertible Notes was converted, at the adjusted conversion price of $0.01 per share, into 465,172,000 shares of the Company’s common stock. December 31, 2018 December 31, 2017 Principle $ 958,611 $ 890,766 Conversion of convertible notes to shares (547,390 ) - Accrued interest - 67,846 Discount (13,938 ) - Total 397,283 958,612 B. In January 2018, the Company received from certain third-party accredited investors $100,000 in consideration for the issuance of convertible promissory notes (the “$100,000 Convertible Notes”) as follows: (i) interest at the rate of 1% per annum; (ii) a conversion price of $0.01 per share of common stock; and (iii) repayable through to January 15, 2019, without penalty. The beneficial conversion feature was valued at $100,000, which resulted in a $100,000 discount recorded as a reduction of debt and an increase to additional paid in capital in the Statement of Stockholders’ Deficit. The discount is amortized to finance expenses in the consolidated statements of Comprehensive Loss over the term of the $100,000 Convertible Notes. On January 23, 2018, $3,000 of the $100,000 Convertible Notes was converted at $0.01 per share into 300,000 shares, based upon the $100,000 Notes conversion price of $0.01 per share of common stock and On December 14 2018, $5,004 of the $100,000 Convertible Notes was converted, at the conversion price of $0.01 per share, into 504,600 shares of the Company’s common stock. December 31, 2018 December 31, 2017 Principle $ 100,000 $ - Conversion of convertible notes to shares (8,004 ) - Discount (3,830 ) - Total 88,166 -

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	Note 4 - Stockholders’ Equity. A. Shares of common stock confer upon their holders the right to receive notice to participate and vote in general meetings of shareholders of the Company, the right to receive dividends, if declared, and the right to receive a distribution of any surplus of assets upon liquidation of the Company. B. Preferred shares confer upon their holders the right to receive dividends when paid to holders of common stock of the Company on an as-converted basis, and the right to receive a distribution of any surplus of assets upon liquidation of the Company before any distribution or payment shall be made to the holders of any common stock. C. Issuances of Common Stock and Warrants during 2018 and 2017 1. On February 24, 2017, Publicis Groupe 90 (“Publicis 90”) invested 500,000 Euros or approximately U$526,000 and the Registrant accepted a Reg S Subscription Agreement from Publicis 90 in consideration for the issuance to Publicis 90 of 1,315,563 restricted shares of the Registrant’s common stock at a subscription price of $0.40 per share. The issuance was made in reliance upon the exemptions provided in Section 4(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation S promulgated by the SEC under the Act. 2. On April 25, 2017, a holder of a convertible note in the principal amount of $100,000 issued in July 2016, converted $10,400 into 74,572, shares based on an adjusted conversion price of $0.14. The conversion price was adjusted on March 22, 2017 pursuant to the provisions of the 2016 Secured Convertible Note Agreement. 3. On June 12, 2017, certain warrant holders holding 1,100,000 Class A Warrants and 1,100,000 Class B Warrants, elected to exercise certain warrants on a cashless basis. In accordance with the 2016 Secured Convertible Note Agreement the Class A warrants and Class B warrants were increased to 5,665,626 each, based on an adjusted share price of $0.14 per share and 3,451,490 Class B Warrants were converted to 1,096,395 shares at $0.14 per share. The exercise price and number of shares issued were adjusted on March 22, 2017. 4. On June 12, 2017, the Company completed the issuance of 125,000 shares of the Company’s common stock to Alpha pursuant to the Company’s agreement with Alpha in the prior year. 5. In July and August 2017, the Company received $80,000 in respect of 571,429 units to two accredited investors for $0.14 per unit. Each unit consist (i) 571,429 shares at a price of $0.14 per share, (ii) 571,429 Class H warrants exercisable for a one-year period in exercise price of $0.14, and (iii) 571,429 Class I warrants exercisable for a two-year period. As of December 31, 2017, the Company had not issued the shares or the warrants to the accredited investors as such, the proceeds were recorded as Receipts on Account of shares in the Company’s shareholders equity statement. On February 8, 2018, the Company issued 571,429 units to two accredited investors in consideration for subscription proceeds of $80,000 which proceeds were received in August 2017. 6. Between January 2018 and April 2018, the Company received the aggregate amount of $1,940,950 in subscription proceeds from certain “accredited investors” in consideration for the issuance of 27,697,855 units (the “Units”) at an offering price of $0.07 per Unit (the “$0.07 Unit Offering”), each consisting of: (i) one (1) share of the Company’s common stock (the “Shares”); (ii) one (1) common stock purchase warrant exercisable for a period of twelve months to purchase one additional Share at an exercise price of $0.14 per Share (the “Class F Warrants”); and (iii) one (1) common stock purchase warrant exercisable for a period of twelve months to purchase one additional Share at an exercise price of $0.28 per Share (the “Class G Warrants”). 7. On January 26, 2018, the Company signed a two-year consulting agreement with Maz Partners, pursuant to which it will to provide investment and corporate finance advice to the Company in consideration for 200,000 Class H Warrants. Each Class H Warrant is exercisable through to January 2020 to purchase one (1) Share at an exercise price of $0.14 per Share. The fair value of these Class H Warrants at the issuance date was $39,845 and was charged to General and administration expenses in the Statement of Comprehensive Loss with a corresponding credit to Additional Paid-in Capital in the Statement of Changes in Stockholders’ Deficit. The fair value was estimated using the Black-Scholes option pricing model and the following weighted average assumptions: share price - $0.24; exercise price - $0.14; expected life - 24 months; annualized volatility - 170.7%; dividend yield - 0%; risk free rate – 0.7%, were charged to General and administration expenses in the Statement of Comprehensive Loss with a corresponding credit to Additional Paid-in Capital in the Statement of Changes in Stockholders’ Deficit. 8. On March 9, 2018, the Company signed a consulting agreement with Ayin, Nun, Chaf, Yeuzt Ltd, pursuant to which it will to provide professional legal advice to the Company in consideration for 550,000 Class H Warrants. Each Class H Warrant is exercisable through to March 2020 to purchase one (1) Share at an exercise price of $0.14 per Share. The fair value of these Class H Warrants at the issuance date was $134,566. The fair value was estimated using the Black-Scholes option pricing model and the following weighted average assumptions: share price - $0.26; exercise price - $0.14; expected life - 24 months; annualized volatility - 244.8%; dividend yield - 0%; risk free rate – 2.4%. $106,531 were charged to General and administration expenses in the Statement of Comprehensive Loss with a corresponding credit to Additional Paid-in Capital in the Statement of Changes in Stockholders’ Deficit. 9. On March 12, 2018, the Company issued a total of 3,629,999 restricted Shares to certain consultants, who were accredited investors, in connection with services rendered during the first quarter of 2018, which Shares were valued at $892,300, based on the closing Share price on the day prior to the issuance date. The above-mentioned amount was recorded as a charge to the Company’s Statement of Comprehensive Loss, with a corresponding credit to Additional Paid in Capital in the Company’s Consolidated Statement of Changes in Stockholders’ Deficit. 10. On March 20, 2018, the Company issued a total of 62,500 restricted Shares in consideration for the exercise of a stock option at an exercise price of $0.01 per Share, which options were granted in connection with services rendered in October 2016. The Company recorded the proceeds on the exercise of the stock option in Additional Paid-in Capital in its Consolidated Statement of Changes in Stockholders’ Deficit. 11. On April 20, 2018, the Company issued a total of 700,000 restricted Shares to certain consultants, who were accredited investors, in connection with services rendered during the second quarter of 2018, which Shares were valued at $112,000, based on the closing share price on the day prior to each of the issuances. The above-mentioned amount was recorded as a charge to the Company’s Statement of Comprehensive Loss, with a corresponding credit to Additional Paid in Capital in the Company’s Statement of Changes in Stockholders’ Equity. 12. As described in Note 3 above, the Company issued a total of 55,543,600 Shares in connection with the conversion of convertible note in amount of $555,390. 13. The following table summarizes information of outstanding warrants issued to investors and consultants in exchange for their services as of December 31, 2018 and 2017: December 31, 2018 Warrants Warrant Term Exercise Price Exercisable Investors – Class F Warrants 27,697,855 January 2019 -April 2019 $ 0.14 27,697,855 Investors – Class G Warrants 27,697,855 January 2019 -April 2019 $ 0.28 27,697,855 Investors - Class H Warrants 1,321,429 January 2019 -March 2020 $ 0.14 1,321,429 Investors - Class I Warrants 571,429 January 2020 $ 0.14 571,429 December 31, 2017 Warrants Warrant Term Exercise Price Exercisable Investors - Class A Warrants 6,334,626 1 year $ 0.14-0.80 6,334,626 Investors - Class B Warrants 5,400,478 5 years $ 0.14 5,400,478 Alimi Ahmed - Class E Warrants (1) 900,000 (1) $ 0.0001 900,000 D. Recent Option Grants During the fiscal year ended December 31, 2017, the Company had outstanding awards for stock options under its 2017 Stock Incentive Plan (the “Plan”). The Plan, which was approved by the Board of Directors on December 1, 2017 and provides for the grant of up to 2 million shares to eligible participants bearing such terms and conditions, including but not limited to vesting provisions, exercise price(s) and other terms as the Board of Directors may reasonably determine from time to time, expires on November 30, 2023. Options granted under the Plan may be exercised on a cash or cashless basis, and the number of shares eligible for grant under the Plan may be increased, and the option exercise price(s) and vesting terms may the adjusted by, the Board of Directors, subject to provisions of the Plan and applicable laws and rules. Any options under the Plans that are canceled or forfeited before expiration become available for future grants. The Board of Directors of the Company administers the Company’s stock incentive compensation and equity-based plans. A summary of the Company’s activity related to options to employees, executives, directors and consultants and related information is as follows: For the year ended December 31, 2018 For the year ended December 31, 2017 Amount of options Weighted average exercise price Aggregate intrinsic value Amount of options Weighted average exercise price Aggregate intrinsic value $ $ $ $ Outstanding at beginning of year 62,500 0.01 4,193,397 0.11 Granted - - - - Exercised (62,500 ) 0.01 - - Cancelled - - - (4,130,397 ) (0.11 ) Outstanding at the end of period - - - 62,500 0.01 Vested and expected-to-vest at end of period - - - 62,500 0.01 - The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value of the Company’s common shares on December 31, 2017 and the exercise price, multiplied by the number of in-the-money stock options on those dates) that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates. The stock options outstanding as of December 31, 2017, have been separated into exercise prices, as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, 2017 2017 2017 0.01 62,500 8.25 62,500 0.01 62,500 8.25 62,500 Compensation expense recorded by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended December 31, 2018 and 2017 was nil and $76,616, respectively and are included in General and Administrative expenses in the Statements of Operations

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5 - Commitments and Contingencies A. The Company received grants to fund research and development projects from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obligated to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% of sales and the total royalties will not exceed the amount of the grants received. As of December 31, 2018, total grants received amounted approximately $222 thousands. The obligation to pay royalties is contingent upon the successful outcome of the Company’s research and development projects and the attainment of sales. The Company has no obligation to pay royalties, if sales are not generated, and if the research and development project fails. B. In April 2017, a lawsuit was filed with the Tel Aviv court by Emerald’s former CEO and founder, claiming certain damages to the total amount of $100,000, under the assertion of wrongful dismissal by the Company. The Company believes these claims to be unsubstantiated and wholly without merit and intends to defend itself against these claims. The Company believes that there is a less than 50% chance of his claim being successful. Accordingly, no provision was recorded in regards to this claim. C. In December 2017, a liquidation request was filed with the Tel Aviv court by a group of former Company’s employees under the assertion of delay of pay and insolvency. On December 20, 2017, a hearing discussion took place according to which the court decision that the Company shall settle its pension debts to the former employees within 21 days and settle its severance debts to them in 60 days, otherwise a winding-up order could be given. The amounts being claimed by the former employees are less than $96,000 and are included in current liabilities. D. On January 29, 2018, the Company transferred the ordinary shares of its former Israeli subsidiary, Emerald Israel, to Attorney Eviatar Knoller, Esq., with offices at 20 Lincoln, Tel Aviv-Jaffa 6713412, as trustee (the “Trustee”). The purpose of the transfer of the management shares to the Trustee, pursuant to resolution of the Registrant’s Board of Directors, was to enable the Trustee to liquidate the management shares and/or the assets of Emerald Israel to satisfy its debts and satisfy its financial obligations to former employees. As a result, the former employees of Emerald Israel commenced an action in a court of competent jurisdiction in Israel to liquidate Emerald Israel and use any assets to satisfy the debts owed to the former employees. E. On April 24, 2018, Emerald Israel reported to the District Court regarding the failure in contracting a buyer for its DermaCompare technology at fair market price and therefore that Emerald Israel was no longer opposed to the requested Liquidation Warrant. On May 1, 2018, the Official Receiver submitted its response to the District Court, stating that according to such announcement of Emerald Israel, it did not oppose the requested Liquidation Warrant either. Based on both the Company’s and the Official Receiver’s position, on May 2, 2018, the District Court issued a Winding-up Order and temporarily nominated Adv. Hanit Nov (attorney) as a Special Executor to Emerald Israel, who is still in the process of winding up Emerald Israel in terms of the court order.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2018
General And Administrative Expenses
General and Administrative Expenses	Note 6 - General and administrative expenses. Year ended December 31, 2018 2017 Professional fees 559,880 480,684 Common stock and warrants issued for services 1,150,675 76,616 Other 63,284 - 1,773,839 557,300

Financing Expenses, Net

Financing Expenses, Net	12 Months Ended
	Dec. 31, 2018
Financing Expenses Net
Financing Expenses, Net	Note 7 - FINANCING EXPENSES, NET Year ended December 31, 2018 2017 Finance loss arising from change in terms of convertible notes (Note 3) 21,622,897 - Amortization of debt discount 1,040,838 Losses from marketable securities 32,758 - Cancellation of Preferred Shares (150,000 ) Other (4,259 ) 307,516 22,542,234 307,516

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 - Income Taxes. The Company is subject to income taxes under the Israeli and U.S. tax laws: Corporate tax rates The Company is subject to Israeli corporate, 24% in 2017 and 23% from 2018. The maximum statutory federal tax rate in the US in 2017 and 2018 is 35%. The Company is not subject to current federal taxes, as it has incurred losses in 2017 and 2018. As of December 31, 2018, the Company generated net operating losses in Israel of approximately $960,000, which may be carried forward and offset against taxable income in the future for an indefinite period. As of December 31, 2018, the Company generated net operating losses for tax in the U.S. of approximately $300,000. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. As of December 31, 2018 As of December 31, 2017 Net loss carry-forward $ 19,604,852 $ 18,344,852 Total deferred tax assets 44,185,284 3,916,297 Valuation allowance (4,185,284 ) (3,916,297 ) Net deferred tax assets $ - $ - On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law in the United States. The Tax Act, among other provisions, introduces changes in the U.S corporate tax rate, business related deductions and credits, and has international tax consequences for companies that operate globally. Most of the changes introduced in the Tax Act are effective beginning on January 1, 2018. As a result of the tax act the maximum statutory federal tax rate was reduced to 21% starting on January 1, 2018. The other effects of the Tax Act provisions are still being identified and evaluated by the Company.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 9 - Related Party Transactions. Other than transactions and balances related to cash and share based compensation to officers and directors and other than the issues of convertible debt and warrants to Alpha (see note 3), and payments in respect of consulting fees to certain shareholders with beneficial holdings of greater that 5% of $148,910 and $ nill during the years ended December 31, 2018 and 2017, the Company did not have any transactions and balances with related parties and executive officers during the years ended December 2018 and 2017.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 10. Subsequent Events. On January 1, 2019, the January 2018 Convertible Notes were extended through to January 31, 2020 and the $100,000 Convertible Notes were extended through to January 14, 2020. On February 7, 2019, Virtual Crypto Technologies, Inc. (the “Company”) entered a share exchange agreement (the “Agreement”) with Algomizer Ltd., an Israeli Corporation (“Algomizer”), pursuant to which Algomizer will assign, transfer and deliver its 99.83% holdings in Viewbix Ltd., an Israeli Corporation, to the Company in exchange for shares of restricted common stock of the Company representing 65% of the issued and outstanding share capital of the Company on a fully diluted basis on the closing date, excluding VCT warrants to purchase shares of common stock, which will expire in 2020 and with an exercise price representing a valuation for VCT equal to $30,000,000 (“Fully Diluted Share Capital”). In addition, upon the earlier of: (a) the launch of a live video product to an American consumer in the U.S by Viewbix Ltd., or (b) the launch of an interactive television product to an American consumer in the U.S Viewbix Ltd., the Company will issue Algomizer additional shares of restricted common stock of the Company representing 5% of the Fully Diluted Share Capital. Furthermore, on the closing date, the Company will issue Algomizer: (i) warrants to purchase shares of restricted common stock of the Company with an exercise price representing a valuation for the Company of $15,000,000 on Fully Diluted Share Capital basis, which will represent 10% of the Fully Diluted Share Capital immediately following the closing for a period of ten years, and (ii) warrants to purchase shares of restricted common stock of the Company with an exercise price representing a valuation for the Company of $25,000,000 on Fully Diluted Share Capital basis, which will represent 10% of the Fully Diluted Share Capital immediately following the closing for a period of ten years. The closing of the Agreement is condition upon the Company filing an amendment to its certificate of incorporation to change the Company’s name to ViewBix Inc., effecting a reverse split of the Company’s shares of common stock at a ratio of 15:1, conversion of the Company’s outstanding debentures into restricted common stock and obtaining a tax pre-ruling from the Israeli Tax Authority relating to the Agreement to be obtained by Algomizer. In addition, the closing is subject to and conditioned upon the approval of the shareholders of the Company. On February 26, 2019, the Majority Consenting Stockholders approved the Stockholder Consent, approving the Reverse Stock Split Certificate of Amendment in order to affect a reverse stock split of the Corporation’s Common Stock on a 1-for-15 basis. The Company will effect such reverse stock split once all approvals for such actions are obtained. Pursuant to the Reverse Stock Split, each fifteen (15) shares of Common Stock will be automatically converted, without any further action by the stockholders, into one share of Common Stock. No fractional shares of Common Stock will be issued as the result of the Reverse Stock Split. Instead, each Stockholder will be entitled to receive one share of Common Stock in lieu of the fractional share that would have resulted from the Reverse Stock Split.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates in the Preparation of Consolidated Financial Statements	Use of estimates in the preparation of consolidated financial statements This Management’s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. As applicable to the consolidated financial statements included elsewhere in this report, the most significant estimates and assumptions relate to (i) the going concern assumptions, (ii) measurement of Convertible Note.
Functional Currency	Functional currency The functional currency of the Company and its subsidiary is the US dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, “Foreign Currency Matters” (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses.
Principles of Consolidation	Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and cash equivalents The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.
Marketable Securities	Marketable Securities The Company accounts for investments in marketable securities in accordance with ASC Topic 320-10, “Investments - Debt and Equity Securities”
Property and Equipment	Property and equipment 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations. 2. Rates of depreciation: % Computers 33 Furniture and office equipment 7-15
Impairment of Long-lived Assets	Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment losses.
Accounting for Obligations and Instruments Potentially to be Settled in the Company's Own Stock	Accounting For Obligations And Instruments Potentially To Be Settled In The Company’s Own Stock: We account for obligations and instruments potentially to be settled in the Company’s stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This guidance addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company’s own stock.
Fair Value of Financial Instruments	Fair Value of Financial Instruments: FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2018 and 2017, the carrying value of certain financial instruments (cash and cash equivalents, other current assets, accounts payable and accrued expenses and employee payable.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. The Company measures its derivative warrant liabilities at fair value at each period. The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Accounting for Convertible Debt Instruments	Accounting For Convertible Debt Instruments We account for convertible debt instruments, which do not meet the definition of a derivative financial instrument per FASB ASC 815, Accounting for Derivative Financial Instruments, in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. This guidance addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Discount on the debt component resulting from allocation of proceeds to the equity component is amortized in the profit and loss statement as finance expense. Allocation of proceeds into equity and debt components of convertible notes issued together with other detachable financial instruments is performed, in relation to the proceeds allocated to the convertible notes, based on the relative fair value of such convertible notes and the other detachable financial instruments issued.
Share-based Compensation	Share-based compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors (including employee stock options under the Company’s stock plans) based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award, net of estimated forfeitures. The Company estimates the fair value of stock options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.
Earnings Per Common Share	Earnings per Common Share Basic net loss per share is computed by dividing net loss, as adjusted to include the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis. Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2018 and December 31, 2017, since all such securities have an anti-dilutive effect.
Revenue Recognition	Revenue recognition The Company follows paragraph 605-10-S99 of the FASB Accounting Standards Codification
Research and Development Expenses, Net	Research and development expenses, net: Research and development expenses are charged to the statement of operations as incurred.
Income Taxes	Income Taxes: We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for consolidated financial statements purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and consolidated financial statements purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
Uncertain Tax Positions	Uncertain Tax Positions : When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
Contingencies	Contingencies The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Recently Issued Accounting Pronouncements	Recently issued accounting pronouncements 1. Accounting Standard Update 2014-09, “Revenue from Contracts with Customers” Commencing January 1, 2018, the Company adopted Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in ASU 2014-09 using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. During 2016, the FASB issued several Accounting Standard Updates (“ASUs”) that focus on certain implementation issues of the new revenue recognition guidance including Narrow-Scope Improvements, Practical Expedients and technical corrections. In accordance with an amendment to ASU 2014-09, introduced by Accounting Standard 2015-14, “Revenue from contracts with Customers – Deferral of the Effective Date”, for a public entity, the amendments in ASU 2014-09 became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). The adoption of ASU 2014-09 did not have a significant impact on its consolidated financial statements. 2. Accounting Standard Update (ASU) No. 2017-11, “ Earnings Per Share” In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Among others, Part I of ASU 2017-11 simplifies the accounting for certain financial instruments with down round features, which is a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Current accounting guidance creates cost and complexity for organizations that issue financial instruments with down round features by requiring, on an ongoing basis, fair value measurement of the entire instrument or conversion option. ASU 2017-11 require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. ASU 2017-11 also addresses navigational concerns within the FASB Accounting Standards Codification related to an indefinite deferral available to private companies. The provisions of the new ASU related to down rounds are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 (fiscal 2019 for the Company). Early adoption is permitted for all entities. The adoption of ASU 2017-11 did not have a significant impact on its consolidated financial statements 3. Accounting Standard Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In June 2018, the FASB issued Accounting Standard Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (ASU 2018-07). ASU 2018-07 aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 will be measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the goods has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based payment awards will be measured at the grant date. With respect to awards with performance conditions, ASU 2018-07 concludes that, consistent with the accounting for employee share-based payment awards, an entity will consider the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions. ASU 2018-07 also requires that the classification of equity classified nonemployee share-based payment awards will continue to be subject to the requirements of Topic 718 unless the award was modified after the goods has been delivered, the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing goods or services. This eliminates the requirement to reassess classification of such awards upon vesting. In addition, ASU 2018-07 includes certain Non-public Entity-Specific Amendments. ASU 2018-07 is effective for Public entities in annual periods beginning after 15 December 2018, and interim periods within those years (first quarter of 2019 for the Company). Early adoption is permitted, including in an interim period, but not before an entity adopts the new revenue guidance (which was adopted by the Company in its interim financial statements for 2018). An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity-classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these nonemployee awards at fair value as of the adoption date. The Company is evaluating the impact of ASU 2018-07 on its financial statements. 4. In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2016-02 (Topic 842) “Leases”. Topic 842 supersedes the lease requirements in Accounting Standards Codification (ASC) Topic 840, “Leases”. Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. ASU No. 2016-02 is effective for interim and annual reporting periods beginning after December 15, 2018. In July 2018, the FASB issued amendments in ASU 2018-11, which provide a transition election to not restate comparative periods for the effects of applying the new standard. This transition election permits entities to change the date of initial application to the beginning of the earliest comparative period presented, or retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements and related disclosures. 5. Commencing January 1, 2018, the Company adopted ASU 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash” (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. This guidance did not have a material impact on the Company’s consolidated financial statements.

General (Tables)

General (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Liabilities Held for Sale	Liabilities held for sale: December 31, 2018 December 31, 2017 Accounts payable and accrued liabilities 287,070 321,934 Accounts payable - related party 76,004 82,331 Employee payable 75,955 98,476 Short term portion of convertible notes 30,496 33,034 Total 469,525 535,775

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Rates of Depreciation on Property and Equipment	% Computers 33 Furniture and office equipment 7-15

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Convertible Notes	December 31, 2018 December 31, 2017 Principle $ 958,611 $ 890,766 Conversion of convertible notes to shares (547,390 ) - Accrued interest - 67,846 Discount (13,938 ) - Total 397,283 958,612 December 31, 2018 December 31, 2017 Principle $ 100,000 $ - Conversion of convertible notes to shares (8,004 ) - Discount (3,830 ) - Total 88,166 -

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Summary of Outstanding Warrants	The following table summarizes information of outstanding warrants issued to investors and consultants in exchange for their services as of December 31, 2018 and 2017: December 31, 2018 Warrants Warrant Term Exercise Price Exercisable Investors – Class F Warrants 27,697,855 January 2019 -April 2019 $ 0.14 27,697,855 Investors – Class G Warrants 27,697,855 January 2019 -April 2019 $ 0.28 27,697,855 Investors - Class H Warrants 1,321,429 January 2019 -March 2020 $ 0.14 1,321,429 Investors - Class I Warrants 571,429 January 2020 $ 0.14 571,429 December 31, 2017 Warrants Warrant Term Exercise Price Exercisable Investors - Class A Warrants 6,334,626 1 year $ 0.14-0.80 6,334,626 Investors - Class B Warrants 5,400,478 5 years $ 0.14 5,400,478 Alimi Ahmed - Class E Warrants (1) 900,000 (1) $ 0.0001 900,000
Summary of Employee Stock Option Activity	A summary of the Company’s activity related to options to employees, executives, directors and consultants and related information is as follows: For the year ended December 31, 2018 For the year ended December 31, 2017 Amount of options Weighted average exercise price Aggregate intrinsic value Amount of options Weighted average exercise price Aggregate intrinsic value $ $ $ $ Outstanding at beginning of year 62,500 0.01 4,193,397 0.11 Granted - - - - Exercised (62,500 ) 0.01 - - Cancelled - - - (4,130,397 ) (0.11 ) Outstanding at the end of period - - - 62,500 0.01 Vested and expected-to-vest at end of period - - - 62,500 0.01 -
Schedule of Stock Options Outstanding Exercise Price Range	The stock options outstanding as of December 31, 2017, have been separated into exercise prices, as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, 2017 2017 2017 0.01 62,500 8.25 62,500 0.01 62,500 8.25 62,500

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
General And Administrative Expenses
Schedule of General and Administrative Expenses	Year ended December 31, 2018 2017 Professional fees 559,880 480,684 Common stock and warrants issued for services 1,150,675 76,616 Other 63,284 - 1,773,839 557,300

Financing Expenses, Net (Tables

Financing Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Financing Expenses Net
Schedule of Financing Expenses, Net	Year ended December 31, 2018 2017 Finance loss arising from change in terms of convertible notes (Note 3) 21,622,897 - Amortization of debt discount 1,040,838 Losses from marketable securities 32,758 - Cancellation of Preferred Shares (150,000 ) Other (4,259 ) 307,516 22,542,234 307,516

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	As of December 31, 2018 As of December 31, 2017 Net loss carry-forward $ 19,604,852 $ 18,344,852 Total deferred tax assets 44,185,284 3,916,297 Valuation allowance (4,185,284 ) (3,916,297 ) Net deferred tax assets $ - $ -

General (Details Narrative)

General (Details Narrative) - USD ($)	Jan. 04, 2018	Dec. 31, 2018	Dec. 31, 2017
Potential value of excess net assets
Finance income		150,000
Revenues		100,000
Net cash used in operating activities		(1,544,053)	$ (630,015)
Alpha Capital Ansalt and Chi Squared Inc [Member] | Series A Preferred Convertible Stock [Member]
Proceeds from liquidation of cancelled shares	$ 150,000
Alpha Capital Ansalt and Chi Squared Inc [Member] | Series A Preferred Convertible Stock [Member] | Maximum [Member]
Proceeds from liquidation of cancelled shares	$ 250,000
Virtual Crypto Israel [Member]
Appointment fee		250,000
Payment for advances on products purchases		150,000
Revenues		100,000
Net cash used in operating activities		$ 1,900,000

General - Schedule of Liabiliti

General - Schedule of Liabilities Held for Sale (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Liabilities held for sale	$ 469,525	$ 535,775
Accounts Payable and Accrued Liabilities [Member]
Liabilities held for sale	287,070	321,934
Accounts Payable - Related Party [Member]
Liabilities held for sale	76,004	82,331
Employee Payable [Member]
Liabilities held for sale	75,955	98,476
Short Term Portion of Convertible Notes [Member]
Liabilities held for sale	$ 30,496	$ 33,034

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Trading losses	$ 40,160

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Rates of Depreciation on Property and Equipment (Details)	Dec. 31, 2018
Computers [Member]
Rates of depreciation on property and equipment	33.00%
Furniture and Office Equipment [Member] | Minimum [Member]
Rates of depreciation on property and equipment	7.00%
Furniture and Office Equipment [Member] | Maximum [Member]
Rates of depreciation on property and equipment	15.00%

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	Dec. 14, 2018	Dec. 09, 2018	Mar. 19, 2018	Jan. 31, 2018	Jan. 24, 2018	Jan. 23, 2018	Dec. 31, 2018	Dec. 31, 2017
Debt instruments, principal amount	$ 100,000					$ 100,000
Conversion price	$ 0.01					$ 0.01
Preferred stock, shares authorized							10,000,000	10,000,000
Conversion amount	$ 5,004					$ 3,000
General and administrative expenses							$ 1,773,839	$ 557,300
Finance expenses							21,622,897
Consideration amount						$ 100,000	555,390
Increased to additional paid in capital							22,600,000
Conversion shares	504,600					300,000
Beneficial conversion feature						$ 100,000
January 2018 Convertible Notes [Member]
Debt instruments, principal amount							958,611	890,766
Conversion price		$ 0.01	$ 0.01		$ 0.01
Conversion amount		$ 465,172	$ 921,800		$ 73,000
Consideration amount					$ 958,611
Conversion shares		465,172,000	921,800		7,300,000
Reduction of debt discount							13,938
$100,000 Convertible Notes [Member]
Debt instruments, principal amount							100,000
Conversion price				$ 0.01
Consideration amount				$ 100,000
Debt bearing interest rate				1.00%
Beneficial conversion feature				$ 100,000
Reduction of debt discount				$ 100,000			3,830
Settlement Agreement [Member]
Debt instruments, principal amount							$ 400,000	400,000
Debt instrument, maturity date							Jun. 19, 2019
Increase in the principal amounts							$ 551,600	$ 551,600
Conversion price							$ 0.14
Settlement Agreement [Member] | Alpha and Chi Squared [Member] | Series A Convertible Preferred Stock [Member]
Conversion price							$ 0.14
Preferred stock, shares authorized							528.82
Stated value and liquidation preference							$ 1,000
Conversion amount							3,778,647
General and administrative expenses							440,684
Finance expenses							$ 219,276

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Notes (Details) - USD ($)	Dec. 31, 2018	Dec. 14, 2018	Jan. 31, 2018	Jan. 23, 2018	Dec. 31, 2017
Principle		$ 100,000		$ 100,000
January 2018 Convertible Notes [Member]
Principle	$ 958,611				$ 890,766
Conversion of convertible notes to shares	(547,390)
Accrued interest					67,846
Discount	(13,938)
Total	397,283				958,612
$100,000 Convertible Notes [Member]
Principle	100,000
Conversion of convertible notes to shares	(8,004)
Discount	(3,830)		$ (100,000)
Total	$ 88,166

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative)

Apr. 20, 2018USD ($)shares

Mar. 20, 2018$ / sharesshares

Mar. 12, 2018USD ($)shares

Mar. 09, 2018USD ($)$ / sharesshares

Feb. 08, 2018USD ($)shares

Jan. 26, 2018USD ($)$ / sharesshares

Jan. 23, 2018USD ($)$ / shares

Jun. 12, 2017$ / sharesshares

Feb. 24, 2017USD ($)$ / sharesshares

Feb. 24, 2017EUR (€)shares

Aug. 31, 2017USD ($)$ / sharesshares

Apr. 30, 2018USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 02, 2018shares

Dec. 31, 2017USD ($)shares

Apr. 25, 2019USD ($)shares

Dec. 14, 2018USD ($)$ / shares

Apr. 25, 2017USD ($)$ / shares

Offering price per share | $ / shares

$ 0.01

Debt Instrument, principal amount | $

$ 100,000

$ 100,000

Proceeds from convertible note | $

$ 100,000

$ 555,390

Convertable note issued

55,543,600

Conversion price per share | $ / shares

$ 0.01

$ 0.01

Proceeds from issuance of common stock | $

General and administration expenses | $

$ 1,773,839

$ 557,300

Restricted shares issued for services, shares

700,000

62,500

Restricted shares issued for services | $

$ 112,000

$ 1,004,299

Share-based compensation awards, grants

Share based employee compensation | $

$ 76,616

2017 Stock Incentive Plan [Member]

Share-based compensation awards, grants

2,000,000

Two Accredited Investors [Member]

Number of common stock shares issued

571,429

Two Accredited Investors [Member] | August 2017 Financing [Member]

Proceeds from issuance of common stock | $

$ 80,000

Accredited Investors [Member]

Offering price per share | $ / shares

$ 0.07

Number of common stock shares issued

27,697,855

Proceeds from issuance of common stock | $

$ 1,940,950

Warrant to purchase of common stock description

(i) one (1) share of the Company's common stock (the "Shares"); (ii) one (1) common stock purchase warrant exercisable for a period of twelve months to purchase one additional Share at an exercise price of $0.14 per Share (the "Class F Warrants"); and (iii) one (1) common stock purchase warrant exercisable for a period of twelve months to purchase one additional Share at an exercise price of $0.28 per Share (the "Class G Warrants").

Consultants [Member]

Number of restricted shares issued | $

$ 892,300

Number of restricted shares issued, shares

3,629,999

Class A Warrant [Member]

Warrants outstanding, shares

1,100,000

Class B Warrant [Member]

Warrants outstanding, shares

1,100,000

Warrant [Member]

Warrant unit offering price per share | $ / shares

$ 0.07

Class H Warrant [Member]

Warrant Exercise Price | $ / shares

$ 0.14

Number of warrants issued

571,429

Warrants exercisable period

1 year

Class I Warrant [Member]

Number of warrants issued

571,429

Warrants exercisable period

2 years

Class F Warrant [Member]

Warrant Exercise Price | $ / shares

0.14

Class G Warrant [Member]

Warrant Exercise Price | $ / shares

$ 0.28

2016 Secured Convertible Note Agreement [Member]

Debt Instrument, principal amount | $

$ 100,000

Proceeds from convertible note | $

$ 10,400

Convertable note issued

74,572

Conversion price per share | $ / shares

$ 0.14

2016 Secured Convertible Note Agreement [Member] | Class A Warrant [Member]

Warrants outstanding, shares

5,665,626

Warrant unit offering price per share | $ / shares

$ 0.14

2016 Secured Convertible Note Agreement [Member] | Class B Warrant [Member]

Warrants outstanding, shares

5,665,626

Warrant unit offering price per share | $ / shares

$ 0.14

Conversion of warrants

3,451,490

Conversion of warrants in to shares

1,096,395

Warrant Exercise Price | $ / shares

$ 0.14

Consulting Agreement [Member] | Class H Warrant [Member]

Warrant unit offering price per share | $ / shares

$ 0.24

Warrant Exercise Price | $ / shares

$ 0.14

Number of warrants issued

200,000

Warrants exercisable period

24 months

Agreement term

2 years

General and administration expenses | $

$ 39,845

Warrant, volatility rate

170.70%

Warrant, dividend yield

0.00%

Warrant, risk free rate

0.70%

Publicis 90 [Member]

Number of restricted shares issued | $

$ 526,000

Number of restricted shares issued, shares

1,315,563

1,315,563

Offering price per share | $ / shares

$ 0.40

Publicis 90 [Member] | EURO [Member]

Number of restricted shares issued | €

€ 500,000

Alpha [Member]

Number of common stock shares issued

125,000

Two Accredited Investors [Member]

Warrant unit offering price per share | $ / shares

$ 0.14

Two Accredited Investors [Member] | Warrant [Member]

Proceeds from issuance of common stock | $

$ 80,000

Number of warrants issued

571,429

Ayin, Nun, Chaf, Yeuzt Ltd [Member] | Consulting Agreement [Member]

General and administration expenses | $

$ 106,531

Ayin, Nun, Chaf, Yeuzt Ltd [Member] | Consulting Agreement [Member] | Class H Warrant [Member]

Warrant unit offering price per share | $ / shares

$ 0.26

Warrant Exercise Price | $ / shares

$ 0.14

Number of warrants issued

550,000

Warrants exercisable period

24 months

General and administration expenses | $

$ 134,566

Warrant, volatility rate

244.80%

Warrant, dividend yield

0.00%

Warrant, risk free rate

2.40%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Aug. 31, 2017	Jun. 12, 2017
Class F Warrant [Member]
Warrant Exercise Price	$ 0.14
Class G Warrant [Member]
Warrant Exercise Price	$ 0.28
Class H Warrant [Member]
Warrant Exercise Price			$ 0.14
Class A Warrant [Member]
Warrants				1,100,000
Class B Warrant [Member]
Warrants				1,100,000
Class E Warrant [Member] | Alimi Ahmed [Member]
Warrants		900,000
Warrant Exercise Price		$ 0.0001
Warrant Exercisable		900,000
Investors [Member] | Class F Warrant [Member]
Warrants	27,697,855
Warrant Term	January 2019 -April 2019
Warrant Exercise Price	$ 0.14
Warrant Exercisable	27,697,855
Investors [Member] | Class G Warrant [Member]
Warrants	27,697,855
Warrant Term	January 2019 -April 2019
Warrant Exercise Price	$ 0.28
Warrant Exercisable	27,697,855
Investors [Member] | Class H Warrant [Member]
Warrants	1,321,429
Warrant Term	January 2019 -March 2020
Warrant Exercise Price	$ 0.14
Warrant Exercisable	1,321,429
Investors [Member] | Class I Warrant [Member]
Warrants	571,429
Warrant Term	January 2020
Warrant Exercise Price	$ 0.14
Warrant Exercisable	571,429
Investors [Member] | Class A Warrant [Member]
Warrants		6,334,626
Warrant Term		1 year
Warrant Exercisable		6,334,626
Investors [Member] | Class A Warrant [Member] | Minimum [Member]
Warrant Exercise Price		$ 0.14
Investors [Member] | Class A Warrant [Member] | Maximum [Member]
Warrant Exercise Price		$ 0.80
Investors [Member] | Class B Warrant [Member]
Warrants		5,400,478
Warrant Term		5 years
Warrant Exercise Price		$ 0.14
Warrant Exercisable		5,400,478

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Employee Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Number of options, Outstanding at beginning of year	62,500	4,193,397
Number of options, Granted
Number of options, Exercised	(62,500)
Number of options, Cancelled		(4,130,397)
Number of options, Outstanding at end of year		62,500
Number of options, Options exercisable at end of period		62,500
Weighted average exercise price, Outstanding at beginning of year	$ 0.01	$ 0.11
Weighted average exercise price, Granted
Weighted average exercise price, Exercised	0.01
Weighted average exercise price, Cancelled		(0.11)
Weighted average exercise price, Outstanding at end of year		0.01
Weighted average exercise price, Options exercisable at end of period		$ 0.01
Aggregate intrinsic value, Outstanding at end of year
Aggregate intrinsic value, Options exercisable at end of period

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Options Outstanding Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Exercise price | $ / shares	$ 0.01
Stock options outstanding	62,500
Weighted average remaining contractual life	8 years 2 months 30 days
Stock options exercisable	62,500
Exercise Price One [Member]
Exercise price | $ / shares	$ 0.01
Stock options outstanding	62,500
Weighted average remaining contractual life	8 years 2 months 30 days
Stock options exercisable	62,500

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2017	Dec. 31, 2018
Total grants received		$ 222,000
Settlement amount to applicants		$ 96,000
Chief Executive Officer and Founder [Member]
Claim from damages	$ 100,000
Sales [Member]
Royalty rate percentage		3.50%

General and Administrative Ex_3

General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
General And Administrative Expenses
Professional fees	$ 559,880	$ 480,684
Common stock and warrants issued for services	1,150,675	76,616
Other	63,284
General and administrative expenses	$ (1,773,839)	$ (557,300)

Financing Expenses, Net - Sched

Financing Expenses, Net - Schedule of Financing Expenses, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Financing Expenses Net
Finance loss arising from change in terms of convertible notes (Note 3)	$ 21,622,897
Amortization of debt discount	1,040,838
Losses from marketable securities	32,758
Cancellation of Preferred Shares	(150,000)
Other	(4,259)	307,516
Financing expenses, net	$ (22,542,234)	$ (307,516)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income tax reconciliation description	As a result of the tax act the maximum statutory federal tax rate was reduced to 21% starting on January 1, 2018.
Israeli [Member]
Corporate tax rate	23.00%	24.00%
Net operating loss carry forwards	$ 960,000
U.S[Member]
Corporate tax rate	35.00%	35.00%
Net operating loss carry forwards	$ 300,000
Net operating losses expiration period	2035

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net loss carry-forward	$ 19,604,852	$ 18,344,852
Total deferred tax assets	44,185,284	3,916,297
Valuation allowance	(4,185,284)	(3,916,297)
Net deferred tax assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Officers and Directors [Member]
Shareholders with beneficial holdings	$ 148,910
Officers and Directors [Member] | Payments in Respect of Consulting Fees [Member]
Due to officers or directors
Chief Executive Officer and Founder [Member]
Shareholders with beneficial holdings
Minimum [Member] | Officers and Directors [Member]
Shareholders with beneficial holdings percentage	5.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Feb. 07, 2019	Jan. 02, 2019
Algomizer Ltd [Member] | Restricted Stock [Member]
Percentage of fully diluted share capital	10.00%
Conversion of warrants	15,000,000
Warrants exercisable term	10 years
Algomizer Ltd [Member] | Restricted Stock [Member] | Arrangement 2 [Member]
Percentage of fully diluted share capital	10.00%
Conversion of warrants	25,000,000
Warrants exercisable term	10 years
Algomizer Ltd [Member] | Viewbix Ltd [Member]
Noncontrolling interest, ownership percentage by noncontrolling owners	99.83%
Issued and outstanding share capital percentage	65.00%
Warrant expiration year	2020
Warrants exercisable	$ 30,000,000
Percentage of fully diluted share capital	5.00%
Share exchange agreement, description	The closing of the Agreement is condition upon the Company filing an amendment to its certificate of incorporation to change the Company's name to ViewBix Inc., effecting a reverse split of the Company's shares of common stock at a ratio of 15:1
Stockholders' equity, reverse stock split	1-for-15 basis
January 2018 Convertible Notes [Member]
Debt instrument, maturity date		Jan. 31, 2020
$100,000 Convertible Notes [Member]
Debt instrument, maturity date		Jan. 14, 2020